chufangao/CTO huggingface dataset:
Clinical trial NCT05148234: BMS-986253 in Myelodysplastic Syndromes
Official title: A Phase I/II Trial of BMS-986253 in Myelodysplastic Syndromes
Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Company closed the trial.
Enrollment: 2.0 (ACTUAL)
Number of arms: 4.0
Start date: 2022-11-29
Primary completion date: 2023-02-02
Completion date: 2023-07-03
Baseline population: Data was collected and reported for one participant enrolled but not treated.
Plan to share individual participant data: YES
IPD sharing description: All collected individual participant data (IPD) will be shared. In addition, all large-scale genomic sequencing data will be shared with subscribers to the database of Genotypes and Phenotypes (dbGaP).
IPD time frame: Data from this study may be requested from other researchers after the completion of the primary endpoint. Genomic data are available once genomic data are uploaded per protocol Genomic Data Sharing (GDS) plan for as long as database is active.
IPD access criteria: Data from this study may be requested by contacting the principal investigator (PI). Genomic data are made available via the database of Genotypes and Phenotypes (dbGaP) through requests to the data custodians.
Clinical trial NCT03472690: QBECO SSI for Clinical and Endoscopic Remission in Moderate to Severe Crohn's Disease
Official title: A Phase 2, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of QBECO SSI for the Induction and Maintenance of Clinical and Endoscopic Remission in Subjects With Moderate to Severe Crohn's Disease
Sponsor: Qu Biologics Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Corporate Decision to terminate study after Lead-In portion of the study completed.
Enrollment: 20.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-06-25
Primary completion date: 2020-12-20
Completion date: 2021-02-25
Plan to share individual participant data: NO
Clinical trial NCT03749447: An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)
Official title: An Extended Access Program to Assess Long Term Safety of Bardoxolone Methyl in Patients With Chronic Kidney Disease
Acronym: EAGLE
Sponsor: Biogen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Discontinuation of all bardoxolone chronic kidney disease programs
Enrollment: 270.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-03-08
Primary completion date: 2023-08-23
Completion date: 2023-08-23
Baseline population: The safety population included all participants who had received at least 1 dose of bardoxolone methyl in the 402-C-1803 study.
Limitations and caveats: Early termination of trial due to discontinuation of all bardoxolone chronic kidney disease programs.
Plan to share individual participant data: YES
IPD sharing description: In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Clinical trial NCT04033328: Study of ORIC-101 in Combination With Enzalutamide
Official title: An Open-Label Phase 1b Study of ORIC-101 in Combination With Enzalutamide in Patients With Metastatic Prostate Cancer Progressing on Enzalutamide
Sponsor: ORIC Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: IND Withdrawn
Enrollment: 41.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-28
Primary completion date: 2022-11-22
Completion date: 2023-12-04
Clinical trial NCT04634825: Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer
Official title: A Phase 2 Open-Label Trial to Evaluate Enoblituzumab in Combination With Retifanlimab or Tebotelimab in the First-Line Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Sponsor: MacroGenics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Based on internal review of safety data
Enrollment: 62.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-17
Primary completion date: 2022-07-29
Completion date: 2022-07-29
Plan to share individual participant data: NO
Clinical trial NCT03563365: The Functional and Emotional Benefits of Replenix Power of Three With Resveratrol
Official title: A Randomized, Investigator Blinded, Single Site, Three Arm Clinical Study to Assess the Functional and Emotional Benefits of Replenix Power of Three Cream With Resveratrol , Replenix Power of Three Cream With Resveratrol With Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5%, and Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5%, Utilized to Treat Subjects With Facial Acne Vulgaris
Sponsor: Yardley Dermatology Associates (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Lack of Funding
Enrollment: 43.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-06-04
Primary completion date: 2021-03-02
Completion date: 2021-03-02
Plan to share individual participant data: NO
Clinical trial NCT03560258: HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) Vaccine Study
Official title: HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) as Therapeutic Vaccination in HIV-Infected Persons With Viral Suppression on Antiretroviral Therapy
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 45.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-03-26
Primary completion date: 2021-02-10
Completion date: 2021-02-10
Baseline population: Participants who received at least one study treatment dose.
Plan to share individual participant data: YES
IPD sharing description: Individual participant data that underlie results in the publication, after deidentification.
IPD time frame: Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by NIH.
IPD access criteria: * With whom?~  * Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.~* For what types of analyses?~  * To achieve aims in the proposal approved by the AIDS Clinical Trials Group.~* By what mechanism will data be made available?~  * Researchers may submit a request for access to data using the AIDS Clinical Trials Group Data Request form at: https://actgnetwork.org/submit-a-proposal/. Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data.
Clinical trial NCT05321251: Topical Insulin Drops for the Treatment of Neurotrophic Keratopathy.
Official title: Topical Insulin Drops for the Treatment of Neurotrophic Keratopathy.
Sponsor: University of Alberta (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: Study never commenced due to logistical issues.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-06-01
Primary completion date: 2023-10-18
Completion date: 2023-10-18
Plan to share individual participant data: NO
Clinical trial NCT03593421: Phase 2 Dose Finding sPIF in Patients With High Panel Reactive Antibodies
Official title: Phase II, Open Label Adaptive Design Dose Finding Study to Investigate Effect of Synthetic PreImplantation Factor (sPIF) in Patients With High Panel Reactive Antibodies
Sponsor: University of Miami (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: BioInceptdecided not to pursue this drug target at this time.
Enrollment: 0.0 (ACTUAL)
Number of arms: 5.0
Start date: 2019-02-01
Primary completion date: 2020-12-01
Completion date: 2020-12-31
Plan to share individual participant data: NO
Clinical trial NCT04487912: Dynamics and Tracer Distribution of Tilmanocept in Early Stage Breast Cancer
Official title: Dynamics and Tracer Distribution of Tilmanocept Using Combined Subareolar and Peritumoral Injection Technique for Scintigraphic Sentinel Lymph Node Detection in Early Stage Breast Cancer
Sponsor: University Hospital, Ghent (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Insufficient patient inclusion
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-24
Primary completion date: 2021-05-01
Completion date: 2021-05-01
Plan to share individual participant data: NO
Clinical trial NCT04483505: Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.
Official title: Rogaratinib, Palbociclib and Fulvestrant in Advanced Hormone Receptor Positive, FGFR1/2/3-positive Breast Cancer: Phase I Clinical Trial Plus an Expansion Cohort
Acronym: ROGABREAST
Sponsor: Fundacion CRIS de Investigación para Vencer el Cáncer (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 9.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-11-25
Primary completion date: 2023-04-04
Completion date: 2023-04-04
Clinical trial NCT05104567: A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
Official title: A Phase 2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR-707) Combined With Other Anticancer Therapies for the Treatment of Participants With Advanced and Metastatic Gastrointestinal Cancer
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Early discontinuation based on strategic sponsor decision not driven by any safety concerns.
Enrollment: 138.0 (ACTUAL)
Number of arms: 7.0
Start date: 2021-12-09
Primary completion date: 2023-07-26
Completion date: 2024-09-09
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT03511222: Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
Official title: A Phase IB Trial of Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Low accrual
Enrollment: 16.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-09-11
Primary completion date: 2019-08-15
Completion date: 2020-05-28
Plan to share individual participant data: NO
Clinical trial NCT03618654: Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma
Official title: Window of Opportunity for Durvalumab (MEDI4736) Plus Metformin Trial of in Squamous Cell Carcinoma of the Head and Neck
Sponsor: Thomas Jefferson University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: COMPLETED 
Enrollment: 38.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-11-01
Primary completion date: 2021-11-20
Completion date: 2022-12-07
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03660553: Simplified Insulin Regimen for the Elderly
Official title: Effect of Simplified Insulin Regimen on Glycemic Control and Quality of Life in an Elderly Population With Type 2 Diabetes
Sponsor: University of Miami (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: PI left University of Miami
Enrollment: 7.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-10-10
Primary completion date: 2022-06-30
Completion date: 2022-06-30
Limitations and caveats: This study was terminated and there was insufficient patient data for statistical analysis.
Plan to share individual participant data: NO
Clinical trial NCT02728531: Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma
Official title: A Pilot Study of Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 18.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-04-18
Primary completion date: 2019-01-16
Completion date: 2023-08-16
Plan to share individual participant data: NO
Clinical trial NCT01246752: Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) (Intermediate Risk) </= 60y. After First CR
Official title: Randomised Trial on Allogeneic Haematopoietic Stem Cell Transplantation in Patients Under the Age of 60 Years With Acute Myeloid Leukemia of Intermediate Risk in First Complete Remission and a Matched Sibling or Unrelated Donor (ETAL-1)
Acronym: AML
Sponsor: University Hospital Carl Gustav Carus (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: decreased recrucial rate as the likelihood of achieving the envisioned patient number in a realistic time-frame was very low.
Enrollment: 143.0 (ACTUAL)
Number of arms: 2.0
Start date: 2011-02-10
Primary completion date: 2020-04-30
Completion date: 2020-04-30
Clinical trial NCT00712582: Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma
Official title: Risk-Adapted Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma
Sponsor: Memorial Sloan Kettering Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 96.0 (ACTUAL)
Number of arms: 3.0
Start date: 2008-07-01
Primary completion date: 2021-03-12
Completion date: 2021-03-12
Clinical trial NCT03430531: Effectiveness of Sphenopalatine Ganglion Block for Post-Dural Puncture Headache
Official title: Effectiveness of Sphenopalatine Ganglion Block for Post-Dural Puncture Headache; A Pilot Study
Sponsor: Milton S. Hershey Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study suspended and subsequently terminated due to Pandemic
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-05-31
Primary completion date: 2020-01-16
Completion date: 2022-03-11
Limitations and caveats: The target enrollment was not reached secondary to the COVID-19 pandemic.
Clinical trial NCT03596450: Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial
Official title: Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Clinical Trial
Sponsor: Novo Nordisk A/S (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 1278.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-07-13
Primary completion date: 2022-06-09
Completion date: 2023-06-09
Baseline population: Full analysis set (FAS) included all randomized participants analyzed according to the treatment group to which they were assigned at randomization.
Plan to share individual participant data: YES
IPD sharing description: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Clinical trial NCT05397171: A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours
Official title: A Phase I/IIa First-in-human, Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: This study was terminated early as per protocol Section 4.4, based on overall risk-benefit profile observed to date. No safety concerns reported. Only Substudy 1 Part A was started; Parts B \& C were not started. Entire Master Protocol was terminated.
Enrollment: 17.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-06-07
Primary completion date: 2023-06-06
Completion date: 2023-06-06
Baseline population: Safety set included all participants who received any amount of investigational product (IP).
Limitations and caveats: This study was terminated early as per protocol Section 4.4, based on overall risk-benefit profile observed to date. No safety concerns reported. Only Sub-study 1 Part A was started; Parts B \& C were not started.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment:~https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.~Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT03594110: EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)
Official title: A Multicentre International Randomized Parallel Group Double-blind Placebo-controlled Clinical Trial of EMPAgliflozin Once Daily to Assess Cardio-renal Outcomes in Patients With Chronic KIDNEY Disease
Sponsor: Boehringer Ingelheim (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 6609.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-31
Primary completion date: 2022-07-05
Completion date: 2024-07-02
Baseline population: Randomised set (RS) included all randomised participants, whether treated or not.
Plan to share individual participant data: YES
IPD sharing description: After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed Document Sharing Agreement. Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.
IPD time frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.
IPD access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.
Clinical trial NCT03994705: Descartes-11 in Multiple Myeloma
Official title: Phase I Safety Study of Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma
Sponsor: Cartesian Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Phase 1 enrollment completed. Further clinical development terminated.
Enrollment: 25.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-08-01
Primary completion date: 2021-05-27
Completion date: 2021-06-11
Plan to share individual participant data: NO
Clinical trial NCT01608451: Randomized Controlled Trial of Neo-adjuvant Progesterone and Vitamin D3 in Women With Large Operable Breast Cancer and Locally Advanced Breast Cancer
Official title: Randomized Controlled Trial of Neo-adjuvant Progesterone and Vitamin D3 in Women With Large Operable Breast Cancer and Locally Advanced Breast Cancer.
Sponsor: Tata Memorial Hospital (OTHER_GOV)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Slow accrual implies that clinical questions being questioned have lost its significance.
Enrollment: 800.0 (ACTUAL)
Number of arms: 4.0
Start date: 2007-09-30
Primary completion date: 2021-08-20
Completion date: 2021-08-20
Clinical trial NCT04033068: Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP (V187-001)
Official title: Observer Blinded, Randomized Trial to Evaluate Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP
Acronym: MV-ZIKA-RSP
Sponsor: Themis Bioscience GmbH (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 48.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-08-02
Primary completion date: 2020-01-30
Completion date: 2020-06-10
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT05156632: Efficacy,Immunogenicity and Safety of COVID-19 Vaccine , Inactivated Booster Dose in Adults Aged 18 Years and Above
Official title: A Multi-center, Randomized, Double-blind, Placebo-controlled Phase Ⅲb Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of COVID-19 Vaccine (Vero Cell), Inactivated Booster Dose in Adults Aged 18 Years and Above
Sponsor: Sinovac Biotech Co., Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: The plan has changed
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2023-02-20
Primary completion date: 2023-02-20
Completion date: 2023-02-20
Clinical trial NCT02548351: Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment
Official title: A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Acronym: REGENERATE
Sponsor: Intercept Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The FDA issued a CRL in response to Intercept's NDA for OCA for the treatment of NASH. Sponsor decided to terminate 747-303 before the planned completion date.
Enrollment: 2477.0 (ACTUAL)
Number of arms: 3.0
Start date: 2015-09-22
Primary completion date: 2023-09-15
Completion date: 2023-09-15